CU20140049A7 - 2-tiopirimidinonas utiles como inhibidores de mieloperoxidasa - Google Patents
2-tiopirimidinonas utiles como inhibidores de mieloperoxidasaInfo
- Publication number
- CU20140049A7 CU20140049A7 CUP2014000049A CU20140049A CU20140049A7 CU 20140049 A7 CU20140049 A7 CU 20140049A7 CU P2014000049 A CUP2014000049 A CU P2014000049A CU 20140049 A CU20140049 A CU 20140049A CU 20140049 A7 CU20140049 A7 CU 20140049A7
- Authority
- CU
- Cuba
- Prior art keywords
- thiopirimidinones
- mieloperoxidasa
- inhibitors
- useful
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Photoreceptors In Electrophotography (AREA)
- Cephalosporin Compounds (AREA)
Abstract
La presente invención se refiere a un compuesto de la Fórmula I, ESPACIO PARA FÓRMULA o a una sal o profármaco de este aceptables desde el punto de vista farmacéutico, en donde R1 contiene un anillo carbocíclico aromático de cinco o seis miembros o un anillo heterocíclico y R2 es una cadena de hidrocarburo lineal en el que uno o dos de los átomos de carbono pueden estar reemplazados por oxígeno, azufre o nitrógeno.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161558605P | 2011-11-11 | 2011-11-11 | |
PCT/IB2012/055949 WO2013068875A1 (en) | 2011-11-11 | 2012-10-28 | 2-thiopyrimidinones |
Publications (1)
Publication Number | Publication Date |
---|---|
CU20140049A7 true CU20140049A7 (es) | 2014-08-28 |
Family
ID=47356235
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CUP2014000049A CU20140049A7 (es) | 2011-11-11 | 2014-04-28 | 2-tiopirimidinonas utiles como inhibidores de mieloperoxidasa |
Country Status (34)
Country | Link |
---|---|
US (4) | US8835449B2 (es) |
EP (1) | EP2776405A1 (es) |
JP (1) | JP5731718B2 (es) |
KR (1) | KR101650262B1 (es) |
CN (1) | CN103917529B (es) |
AP (1) | AP2014007621A0 (es) |
AR (1) | AR088805A1 (es) |
AU (1) | AU2012335220B2 (es) |
BR (1) | BR112014011254A2 (es) |
CA (1) | CA2853024C (es) |
CL (1) | CL2014000996A1 (es) |
CO (1) | CO6960543A2 (es) |
CR (1) | CR20140179A (es) |
CU (1) | CU20140049A7 (es) |
DO (1) | DOP2014000098A (es) |
EA (1) | EA027324B1 (es) |
EC (1) | ECSP14004595A (es) |
GE (1) | GEP201706656B (es) |
GT (1) | GT201400090A (es) |
HK (1) | HK1196603A1 (es) |
IL (2) | IL232425A (es) |
MA (1) | MA35638B1 (es) |
MD (1) | MD20140044A2 (es) |
MX (1) | MX351299B (es) |
NI (1) | NI201400042A (es) |
PE (1) | PE20161219A1 (es) |
PH (1) | PH12014501032A1 (es) |
SG (1) | SG11201401531RA (es) |
TN (1) | TN2014000195A1 (es) |
TW (2) | TWI526433B (es) |
UA (1) | UA108713C2 (es) |
UY (1) | UY34442A (es) |
WO (1) | WO2013068875A1 (es) |
ZA (1) | ZA201403589B (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2386555A1 (en) | 2010-05-13 | 2011-11-16 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities |
GEP201706656B (en) | 2011-11-11 | 2017-04-25 | Pfizer | 2-thiopyrimidinones |
EP2592078A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
US9518050B2 (en) | 2012-12-18 | 2016-12-13 | Almirall, S.A. | Cyclohexyl and quinuclidinyl carbamate derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activity |
TWI643853B (zh) | 2013-02-27 | 2018-12-11 | 阿爾米雷爾有限公司 | 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類 |
TWI641373B (zh) | 2013-07-25 | 2018-11-21 | 阿爾米雷爾有限公司 | 具有蕈毒鹼受體拮抗劑和β2腎上腺素受體促效劑二者之活性的2-胺基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽 |
TW201517906A (zh) | 2013-07-25 | 2015-05-16 | Almirall Sa | 含有maba化合物和皮質類固醇之組合 |
TW201617343A (zh) | 2014-09-26 | 2016-05-16 | 阿爾米雷爾有限公司 | 具有β2腎上腺素促效劑及M3蕈毒拮抗劑活性之新穎雙環衍生物 |
US9616063B2 (en) | 2014-12-01 | 2017-04-11 | Astrazeneca Ab | 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase |
WO2016178113A1 (en) | 2015-05-05 | 2016-11-10 | Pfizer Inc. | 2-thiopyrimidinones |
JP2021501764A (ja) | 2017-11-02 | 2021-01-21 | アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | B型肝炎ウイルス(hbv)に対して有効な新規高活性アミノチアゾール置換インドール−2−カルボキサミド |
US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
WO2024038131A1 (en) | 2022-08-18 | 2024-02-22 | Astrazeneca Ab | Inhibitors of myeloperoxidase |
Family Cites Families (165)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4088751A (en) | 1972-04-07 | 1978-05-09 | Colgate-Palmolive Company | Self-heating cosmetic |
US4171429A (en) | 1977-03-29 | 1979-10-16 | Research Corporation | Pyrimidine to pyrimidine transformation process |
DE3065190D1 (en) | 1979-11-05 | 1983-11-10 | Beecham Group Plc | Enzyme derivatives, and their preparation |
JPS5770693A (en) | 1980-10-22 | 1982-05-01 | Fuji Photo Film Co Ltd | Desensitizing composition |
WO1989010701A1 (en) | 1988-05-05 | 1989-11-16 | Basf Aktiengesellschaft | Substances based on uracil-derivates for stimulating growth and reducing fat in animals |
KR0155168B1 (ko) | 1989-09-29 | 1998-11-16 | 미우라 아끼라 | 6-치환된 아시클로피리미딘 뉴클레오시드 유도체 및 이를 활성성분으로 함유하는 항비루스제 |
JPH0699170B2 (ja) | 1990-01-19 | 1994-12-07 | 日東紡績株式会社 | 耐火被覆材 |
JPH0525144A (ja) | 1991-04-15 | 1993-02-02 | Nissan Chem Ind Ltd | ウラシル誘導体及び有害生物防除剤 |
JPH0525142A (ja) | 1991-07-12 | 1993-02-02 | Nissan Chem Ind Ltd | ウラシル誘導体及び有害生物防除剤 |
JPH0543555A (ja) | 1991-08-13 | 1993-02-23 | Nissan Chem Ind Ltd | ウラシル誘導体及び有害生物防除剤 |
TW284688B (es) | 1991-11-20 | 1996-09-01 | Takeda Pharm Industry Co Ltd | |
GB2263639A (en) | 1992-01-28 | 1993-08-04 | Merck & Co Inc | Substituted pyrimidinones as neurotensin antagonists |
JPH063761A (ja) | 1992-06-19 | 1994-01-14 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料 |
US6444656B1 (en) | 1992-12-23 | 2002-09-03 | Biochem Pharma, Inc. | Antiviral phosphonate nucleotides |
KR0151811B1 (ko) | 1993-12-21 | 1998-10-15 | 강박광 | 신규한 항바이러스성 2,4-피리미딘디온 유도체 및 그의 제조방법 |
JP3781200B2 (ja) | 1994-04-27 | 2006-05-31 | コニカミノルタホールディングス株式会社 | ハロゲン化銀写真感光材料の処理方法 |
JP3261641B2 (ja) | 1994-04-28 | 2002-03-04 | コニカ株式会社 | ハロゲン化銀写真感光材料の処理方法 |
US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
US6268369B1 (en) | 1994-11-16 | 2001-07-31 | Synaptic Pharmaceutical Corporation | 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines |
NZ297278A (en) | 1994-11-16 | 1999-06-29 | Synaptic Pharma Corp | 4-aryl dihydropyrimidine derivatives end medicaments |
WO1997017969A1 (en) | 1995-11-16 | 1997-05-22 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
US6228861B1 (en) | 1995-11-16 | 2001-05-08 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
US5719190A (en) | 1996-02-28 | 1998-02-17 | Pfizer Inc. | Inhibition of myeloperoxidase activity |
US6172066B1 (en) | 1996-05-16 | 2001-01-09 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
WO1997042956A1 (en) | 1996-05-16 | 1997-11-20 | Synaptic Pharmaceutical Corporation | Didhydropyrimidines and uses thereof |
US6245773B1 (en) | 1996-05-16 | 2001-06-12 | Synaptic Pharmaceutical Corporation | 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines |
DE19647380A1 (de) | 1996-11-15 | 1998-05-20 | Hoechst Ag | 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten |
WO1998024780A2 (en) | 1996-12-05 | 1998-06-11 | Amgen Inc. | Substituted pyrimidinone and pyridinone compounds and their use |
JP2002514195A (ja) | 1996-12-05 | 2002-05-14 | アムジエン・インコーポレーテツド | 置換ピリミジン化合物およびそれの使用 |
US6096753A (en) | 1996-12-05 | 2000-08-01 | Amgen Inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
PT958296E (pt) | 1996-12-31 | 2003-11-28 | Reddys Lab Ltd Dr | Compostos heterociclicos processo para a sua preparacao composicoes farmaceuticas contendo-os e sua utilizacao no tratamento da diabetes e doencas relacionadas |
TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
DE19731784A1 (de) | 1997-07-24 | 1999-02-04 | Bayer Ag | Substituierte N-Aryl-N-thioxocarbonyl-sulfonamide |
US6130340A (en) | 1998-01-13 | 2000-10-10 | President And Fellows Of Harvard College | Asymmetric cycloaddition reactions |
US6211370B1 (en) | 1998-01-13 | 2001-04-03 | Harvard University | Asymmetric cycloaddition reactions |
AU4084599A (en) | 1998-05-18 | 1999-12-06 | Oklahoma Medical Research Foundation | Resveratrol inhibition of myeloperoxidase |
AU767456B2 (en) | 1998-07-06 | 2003-11-13 | Bristol-Myers Squibb Company | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
CA2252144A1 (en) | 1998-10-16 | 2000-04-16 | University Of Alberta | Dual action anticancer prodrugs |
DE19918725A1 (de) | 1999-04-24 | 2000-10-26 | Bayer Ag | Substituierte N-Cyano-sulfonsäureanilide |
CN1286822C (zh) * | 1999-05-01 | 2006-11-29 | 史密丝克莱恩比彻姆有限公司 | 嘧啶酮化合物 |
KR100699512B1 (ko) | 1999-06-02 | 2007-03-26 | 얀센 파마슈티카 엔.브이. | 아미노알킬 치환된 (벤조디옥산, 벤조푸란 또는 벤조피란)유도체 |
IT1307786B1 (it) * | 1999-07-22 | 2001-11-19 | Bracco Spa | Analoghi di ceramidi, processo per la loro preparazione e loro usocome antitumorali. |
FR2796945B1 (fr) * | 1999-07-30 | 2002-06-28 | Sod Conseils Rech Applic | Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments |
JP2001131133A (ja) | 1999-08-23 | 2001-05-15 | Sankyo Co Ltd | 新規ミエロペルオキシダーゼ阻害物質およびその製造方法 |
MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
GB2362101A (en) | 2000-05-12 | 2001-11-14 | Astrazeneca Ab | Treatment of chronic obstructive pulmonary disease |
GB0013655D0 (en) | 2000-06-05 | 2000-07-26 | Prolifix Ltd | Therapeutic compounds |
JO2352B1 (en) | 2000-06-22 | 2006-12-12 | جانسين فارماسيوتيكا ان. في | Compounds for the treatment of non-adaptation of the bottom of the uterus |
WO2002006245A1 (en) | 2000-07-05 | 2002-01-24 | Synaptic Pharmarceutical Corporation | Selective melanin concentrating hormone-1 (mch1) receptor antagonists and uses thereof |
US6720324B2 (en) | 2000-07-05 | 2004-04-13 | Synaptic Pharmaceutical Corporation | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof |
DE60102304T2 (de) | 2000-07-14 | 2005-02-17 | Akzo Nobel N.V. | Stabilisatorensystem, das hydroxysäuren enthält |
DE10034800A1 (de) | 2000-07-18 | 2002-01-31 | Bayer Ag | Substituierte Benzostickstoffheterocyclen |
DE10034803A1 (de) | 2000-07-18 | 2002-01-31 | Bayer Ag | Substituierte Sulfonsäureanilide |
US6562967B2 (en) | 2000-07-31 | 2003-05-13 | Brandeis University | Kinetic resolutions of chiral 2-and-3-substituted carboxylic acids |
WO2003011799A1 (en) | 2000-07-31 | 2003-02-13 | Brandeis University | Kinetic resolutions of chirat 3- and 3-substituted carboxylic acids |
CA2416303A1 (en) | 2000-07-31 | 2002-02-07 | Brandeis University | Kinetic resolutions of chiral 2- and 3-substituted carboxylic acids |
US20030124512A1 (en) | 2000-10-18 | 2003-07-03 | Lieven Stuyver | Simultaneous quantification of nucleic acids in diseased cells |
KR101195019B1 (ko) | 2000-10-18 | 2012-10-29 | 파마셋 인코포레이티드 | 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드 |
DE10108995A1 (de) | 2001-02-23 | 2002-09-05 | Abbott Gmbh & Co Kg | Substituierte Pyrimidinon-Derivate als Liganden von Integrinrezeptoren |
AU2002252183A1 (en) | 2001-03-06 | 2002-09-19 | Biocryst Pharmaceuticals, Inc. | Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases |
DK1387893T3 (da) | 2001-05-08 | 2007-02-19 | Astrazeneca Ab | Assay til detektion af inhibitorer af enzymet myeloperoxidase |
ATE550320T1 (de) | 2001-08-10 | 2012-04-15 | Shionogi & Co | Antivirales mittel |
US6969715B2 (en) | 2001-10-03 | 2005-11-29 | Pharmacia Corporation | 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade |
MXPA04003170A (es) | 2001-10-03 | 2004-07-08 | Pharmacia Corp | Compuestos policiclicos, sustituidos, provisto de 5 miembros, utiles para la inhibicion selectiva de la cascada de coagulacion. |
US20040106626A1 (en) | 2001-10-03 | 2004-06-03 | Pharmacia Corporation | 6-Membered unsaturated heterocyclic compounds useful for selective inhibition of the coagulation cascade |
EP1482940A2 (en) | 2001-10-03 | 2004-12-08 | Pharmacia Corporation | Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade |
AU2003205536A1 (en) | 2002-01-11 | 2003-07-24 | Statens Serum Institut | Anti-retroviral 5,6-disubstituted acyclopyrimidine nucleoside derivatives |
EP1478437B1 (en) | 2002-02-27 | 2005-08-31 | Pfizer Products Inc. | Acc inhibitors |
AU2003216585A1 (en) | 2002-04-10 | 2003-10-20 | Orchid Chemicals And Pharmaceuticals Limited | Pyrimidinedione derivatives useful for the treatment of inflammation and immunological diseases |
AR039385A1 (es) | 2002-04-19 | 2005-02-16 | Astrazeneca Ab | Derivados de tioxantina como inhibidores de la mieloperoxidasa |
PL374162A1 (en) | 2002-05-16 | 2005-10-03 | Bayer Cropscience Gmbh | Pyridine carboxamide derivatives and their use as pesticides |
EP1394242A3 (en) | 2002-08-07 | 2004-04-21 | Rohm And Haas Company | Cyclic thioureas and their use as additives for lubricating oils |
EP1394241A1 (en) | 2002-08-07 | 2004-03-03 | Rohm And Haas Company | Cyclic thioureas as additives for lubricating oils |
AU2003274652A1 (en) | 2002-10-23 | 2004-05-13 | Obetherapy Biotechnology | Compounds, compositions and methods for modulating fat metabolism |
WO2004073703A1 (en) | 2003-02-21 | 2004-09-02 | Tripep Ab | Glycinamide derivative for inhibiting hiv replication |
US20050096319A1 (en) | 2003-02-21 | 2005-05-05 | Balzarini Jan M.R. | Identification of compounds that inhibit replication of human immunodeficiency virus |
AU2004228069B2 (en) | 2003-04-07 | 2011-09-08 | Cortical Pty Ltd | Novel methods for the treatment of inflammatory diseases |
SE0301232D0 (sv) * | 2003-04-25 | 2003-04-25 | Astrazeneca Ab | Novel use |
US7485604B2 (en) | 2003-05-27 | 2009-02-03 | Fujifilm Corporation | Lubricant composition and method for using and preparing thereof |
US7572581B2 (en) | 2003-06-30 | 2009-08-11 | Roche Molecular Systems, Inc. | 2′-terminator nucleotide-related methods and systems |
US7947817B2 (en) | 2003-06-30 | 2011-05-24 | Roche Molecular Systems, Inc. | Synthesis and compositions of 2'-terminator nucleotides |
WO2005063751A1 (en) | 2003-12-22 | 2005-07-14 | Gilead Sciences, Inc. | 4’-substituted carbovir-and abacavir-derivatives as well as related compounds with hiv and hcv antiviral activity |
GEP20094679B (en) | 2004-03-15 | 2009-05-10 | Takeda Pharmaceuticals Co | Dipeptidyl peptidase inhibitors |
PL1753748T3 (pl) | 2004-05-12 | 2010-01-29 | Pfizer Prod Inc | Pochodne proliny i ich zastosowanie jako inhibitorów peptydazy dipeptylowej IV |
US7928207B2 (en) | 2004-06-28 | 2011-04-19 | Roche Molecular Systems, Inc | Synthesis and compositions of nucleic acids comprising 2′-terminator nucleotides |
US7745125B2 (en) | 2004-06-28 | 2010-06-29 | Roche Molecular Systems, Inc. | 2′-terminator related pyrophosphorolysis activated polymerization |
EP1616874A1 (en) | 2004-07-14 | 2006-01-18 | Universiteit Gent | Mono- and bicyclic compounds with therapeutic activity and pharmaceutical compositions including them |
US7485729B2 (en) | 2004-08-12 | 2009-02-03 | King Industries, Inc. | Organometallic compositions and coating compositions |
US20060036007A1 (en) | 2004-08-12 | 2006-02-16 | King Industries, Inc. | Organometallic compositions and coating compositions |
WO2006031806A2 (en) | 2004-09-10 | 2006-03-23 | Atherogenics, Inc. | 2-thiopyrimidinones as therapeutic agents |
GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
WO2006070292A2 (en) | 2004-10-12 | 2006-07-06 | Queen's University At Kingston | Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents |
SE0402591D0 (sv) | 2004-10-25 | 2004-10-25 | Astrazeneca Ab | Novel use |
MY140748A (en) | 2004-12-06 | 2010-01-15 | Astrazeneca Ab | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy |
US20060194821A1 (en) | 2005-02-18 | 2006-08-31 | The Brigham And Women's Hospital, Inc. | Compounds inhibiting the aggregation of superoxide dismutase-1 |
EP1731911A1 (fr) | 2005-06-07 | 2006-12-13 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Procédé utile pour la détection d'encéphalopathies |
US7399786B2 (en) | 2005-06-30 | 2008-07-15 | Bexel Pharmaceuticals, Inc. | Derivatives of amino acids for treatment of obesity and related disorders |
US8481697B2 (en) | 2005-07-01 | 2013-07-09 | Dako Denmark A/S | Nucleic acid base pairs |
EP1920073A2 (en) | 2005-07-01 | 2008-05-14 | Dako Denmark A/S | Method of simultaneously visualizing multiple biological targets |
US7879997B2 (en) | 2005-08-12 | 2011-02-01 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
JP5144532B2 (ja) | 2005-11-30 | 2013-02-13 | バーテックス ファーマシューティカルズ インコーポレイテッド | c−Met阻害剤及び用法 |
JP5094416B2 (ja) | 2005-12-28 | 2012-12-12 | 武田薬品工業株式会社 | 糖尿病治療剤 |
DE102006000649A1 (de) | 2006-01-03 | 2007-07-05 | Degussa Gmbh | Universell einsetzbare Zusammensetzungen |
DE102006000651A1 (de) | 2006-01-03 | 2007-07-12 | Degussa Gmbh | Präparation aus Ionischen Flüssigkeiten und Harzen |
JP5025142B2 (ja) | 2006-02-27 | 2012-09-12 | 株式会社東芝 | モータ制御装置 |
JP5025144B2 (ja) | 2006-02-28 | 2012-09-12 | Jx日鉱日石エネルギー株式会社 | 内燃機関用潤滑油組成物 |
TW200806667A (en) | 2006-04-13 | 2008-02-01 | Astrazeneca Ab | New compounds |
ES2487967T3 (es) | 2006-04-20 | 2014-08-25 | Pfizer Products Inc. | Compuestos amido heterocíclicos condensados con fenilo para la prevención y el tratamiento de enfermedades mediadas por la glucoquinasa |
US8771626B2 (en) | 2006-05-31 | 2014-07-08 | E I Du Pont De Nemours And Company | Process for purifying perfluorinated products |
CN101460501A (zh) * | 2006-06-05 | 2009-06-17 | 阿斯利康(瑞典)有限公司 | 作为髓过氧化物酶抑制剂的吡咯并[3,2-d]嘧啶-4-酮衍生物 |
TW200804383A (en) | 2006-06-05 | 2008-01-16 | Astrazeneca Ab | New compounds |
DK2048145T3 (da) | 2006-08-04 | 2011-04-04 | Toyama Chemical Co Ltd | Forstærker af aktiviteten af proteinkinase C indeholdende alkyletherderivat eller et salt deraf |
WO2008023249A1 (en) | 2006-08-24 | 2008-02-28 | Chemfit Speciality Chemicals (Pty) Ltd | Polyvinylchloride composition |
US20080193411A1 (en) | 2006-11-21 | 2008-08-14 | Genelabs Technologies, Inc. | Anti-viral Compounds |
AP2009004880A0 (en) | 2006-11-29 | 2009-06-30 | Pfizer Prod Inc | Spiroketone acetyl-COA carboxylase inhibitors |
US20080153697A1 (en) | 2006-12-22 | 2008-06-26 | E. I. Dupont De Nemours And Company | Mixtures of ammonia and ionic liquids |
US8633186B2 (en) | 2007-06-08 | 2014-01-21 | Senomyx Inc. | Modulation of chemosensory receptors and ligands associated therewith |
US7928111B2 (en) | 2007-06-08 | 2011-04-19 | Senomyx, Inc. | Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors |
US8354421B2 (en) | 2007-06-29 | 2013-01-15 | Korea Research Insitute Of Chemical Technology | HIV reverse transcriptase inhibitors |
MX2009013804A (es) | 2007-06-29 | 2010-02-03 | Korea Res Inst Chem Tech | Inhibidores novedosos de transcriptasa inversa de vih. |
US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
JP5043555B2 (ja) | 2007-08-08 | 2012-10-10 | 株式会社カネカ | 硬化性組成物 |
US20090054468A1 (en) | 2007-08-23 | 2009-02-26 | Astrazeneca Ab | New Use 938 |
US20090053176A1 (en) | 2007-08-23 | 2009-02-26 | Astrazeneca Ab | New Combination 937 |
WO2009055917A1 (en) | 2007-11-02 | 2009-05-07 | Methylgene Inc. | Inhibitors of histone deacetylase |
GB0722680D0 (en) | 2007-11-19 | 2007-12-27 | Topotarget As | Therapeutic compounds and their use |
JP2009167179A (ja) | 2007-12-21 | 2009-07-30 | Daiichi Sankyo Co Ltd | 環状アミン化合物を含有する医薬 |
CN102036956A (zh) | 2008-03-21 | 2011-04-27 | 柯罗瑞恩制药有限公司 | 取代的吡咯烷和哌啶化合物、它们的衍生物、以及用于治疗疼痛的方法 |
US8236446B2 (en) | 2008-03-26 | 2012-08-07 | Ada Technologies, Inc. | High performance batteries with carbon nanomaterials and ionic liquids |
EP3042660A3 (en) | 2008-04-15 | 2016-10-26 | RFS Pharma, LLC. | Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections |
US8277691B2 (en) | 2008-05-05 | 2012-10-02 | Ada Technologies, Inc. | High performance carbon nanocomposites for ultracapacitors |
ES2545231T3 (es) | 2008-05-28 | 2015-09-09 | Pfizer Inc. | Inhibidores de pirazoloespirocetona acetil-CoA carboxilasa |
JP2011521940A (ja) | 2008-05-28 | 2011-07-28 | ファイザー・インク | ピラゾロスピロケトンアセチルCoAカルボキシラーゼ阻害剤 |
WO2010013161A1 (en) | 2008-07-29 | 2010-02-04 | Pfizer Inc. | Fluorinated heteroaryls |
RS52236B (en) | 2008-08-28 | 2012-10-31 | Pfizer Inc. | DIOKASA-BICYCLE DERIVATIVES (3.2.1) OCTOBER-2,3,4-TRIOLA |
GB0818063D0 (en) * | 2008-10-02 | 2008-11-05 | Univ Dundee | Compounds |
JP5206367B2 (ja) | 2008-11-27 | 2013-06-12 | コニカミノルタエムジー株式会社 | ウレア化合物を含む有機圧電材料 |
WO2010086820A1 (en) | 2009-02-02 | 2010-08-05 | Pfizer Inc. | 4-amino-5-oxo-7, 8-dihydropyrimido [5,4-f] [1,4] oxazepin-6 (5h) -yl) phenyl derivatives, pharmaceutical compositions and uses thereof |
CA2754681C (en) | 2009-03-11 | 2014-01-07 | Pfizer Inc. | Benzofuranyl derivatives used as glucokinase inhibitors |
US20110319379A1 (en) | 2009-03-11 | 2011-12-29 | Corbett Jeffrey W | Substituted Indazole Amides And Their Use As Glucokinase Activators |
EP2408780A2 (en) | 2009-03-20 | 2012-01-25 | Pfizer Inc. | 3-oxa-7-azabicycloý3.3.1¨nonanes |
BRPI1007600A2 (pt) | 2009-04-23 | 2019-09-24 | Invasc Therapeutics Inc | composições e métodos para tratamento de doenças cardiovasculares |
US20100272783A1 (en) | 2009-04-24 | 2010-10-28 | Novabay Pharmaceuticals, Inc. | Methods of Treating Infections of the Nail |
WO2010128425A1 (en) | 2009-05-08 | 2010-11-11 | Pfizer Inc. | Gpr 119 modulators |
JP2012526096A (ja) | 2009-05-08 | 2012-10-25 | ファイザー・インク | Gpr119調節因子 |
EP2435043A1 (en) | 2009-05-27 | 2012-04-04 | Université Libre de Bruxelles | 3-alkyl-5-fluoroindole derivatives as myeloperoxidase inhibitors |
WO2010138901A1 (en) | 2009-05-29 | 2010-12-02 | Biogen Idec Ma Inc | Carboxylic acid-containing compounds, derivatives thereof, and related methods of use |
AU2010255422B2 (en) | 2009-06-05 | 2014-04-10 | Pfizer Inc. | 1- ( piperidin-4-yl) -pyrazole derivatives as GPR 119 modulators |
PL2445502T5 (pl) | 2009-06-25 | 2023-03-13 | Alkermes Pharma Ireland Limited | Związki heterocykliczne do leczenia zaburzeń neurologicznych i psychologicznych |
WO2010151711A1 (en) | 2009-06-25 | 2010-12-29 | Alkermes, Inc. | Prodrugs of nh-acidic compounds |
US9790252B2 (en) | 2009-07-01 | 2017-10-17 | Cornell University | 2-fluorinated riboses and arabinoses and methods of use and synthesis |
WO2011005611A1 (en) | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Neuromedin u receptor agonists and uses thereof |
DE102009037300A1 (de) | 2009-08-14 | 2011-02-17 | Merck Patent Gmbh | Tetracyanoborate als Schmierstoffe |
WO2011045415A2 (en) | 2009-10-15 | 2011-04-21 | Guerbet | New imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases |
WO2011057220A2 (en) | 2009-11-09 | 2011-05-12 | Northwestern University | Compositions and methods for treating lymphoma |
FR2953145B1 (fr) | 2009-11-30 | 2013-07-19 | Inst Francais Du Petrole | Solution absorbante contenant un inhibiteur de degradation derive de la pyrimidine ou de la triazine et procede d'absorption de composes acides contenus dans un effluent gazeux |
WO2011094890A1 (en) | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
WO2011097607A1 (en) | 2010-02-08 | 2011-08-11 | Southern Research Institute | Anti-viral treatment and assay to screen for anti-viral agent |
WO2011109799A1 (en) | 2010-03-05 | 2011-09-09 | Karyopharm Therapeutics, Inc. | Nuclear transport modulatiors and uses thereof |
ES2691671T3 (es) | 2010-06-24 | 2018-11-28 | Alkermes Pharma Ireland Limited | Profármacos de compuestos NH-acídicos: derivados de éster, carbonato, carbamato y fosfonato |
WO2012016133A2 (en) | 2010-07-29 | 2012-02-02 | President And Fellows Of Harvard College | Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers |
ES2352926B1 (es) | 2010-12-07 | 2012-01-12 | Universidad De Granada | Fenucil deuterado y derivados, procedimiento para su preparación y usos de los mismos. |
GEP201706656B (en) | 2011-11-11 | 2017-04-25 | Pfizer | 2-thiopyrimidinones |
JP6003761B2 (ja) | 2013-03-27 | 2016-10-05 | 富士ゼロックス株式会社 | 送風管、送風装置及び画像形成装置 |
WO2016178113A1 (en) * | 2015-05-05 | 2016-11-10 | Pfizer Inc. | 2-thiopyrimidinones |
-
2012
- 2012-10-28 GE GEAP201213463A patent/GEP201706656B/en unknown
- 2012-10-28 MD MDA20140044A patent/MD20140044A2/ro not_active Application Discontinuation
- 2012-10-28 AU AU2012335220A patent/AU2012335220B2/en not_active Ceased
- 2012-10-28 BR BR112014011254A patent/BR112014011254A2/pt not_active Application Discontinuation
- 2012-10-28 WO PCT/IB2012/055949 patent/WO2013068875A1/en active Application Filing
- 2012-10-28 MX MX2014005721A patent/MX351299B/es active IP Right Grant
- 2012-10-28 CN CN201280055082.9A patent/CN103917529B/zh not_active Expired - Fee Related
- 2012-10-28 EA EA201490688A patent/EA027324B1/ru not_active IP Right Cessation
- 2012-10-28 UA UAA201404418A patent/UA108713C2/uk unknown
- 2012-10-28 JP JP2014540581A patent/JP5731718B2/ja not_active Expired - Fee Related
- 2012-10-28 CA CA2853024A patent/CA2853024C/en not_active Expired - Fee Related
- 2012-10-28 SG SG11201401531RA patent/SG11201401531RA/en unknown
- 2012-10-28 KR KR1020147015697A patent/KR101650262B1/ko active IP Right Grant
- 2012-10-28 PE PE2014001103A patent/PE20161219A1/es not_active Application Discontinuation
- 2012-10-28 AP AP2014007621A patent/AP2014007621A0/xx unknown
- 2012-10-28 EP EP12799609.8A patent/EP2776405A1/en not_active Withdrawn
- 2012-11-07 US US13/670,852 patent/US8835449B2/en not_active Expired - Fee Related
- 2012-11-07 TW TW104103035A patent/TWI526433B/zh not_active IP Right Cessation
- 2012-11-07 TW TW101141370A patent/TWI480269B/zh not_active IP Right Cessation
- 2012-11-08 AR ARP120104212A patent/AR088805A1/es unknown
- 2012-11-09 UY UY0001034442A patent/UY34442A/es not_active Application Discontinuation
-
2013
- 2013-05-02 US US13/875,604 patent/US8841314B2/en active Active
-
2014
- 2014-04-17 CL CL2014000996A patent/CL2014000996A1/es unknown
- 2014-04-22 CR CR20140179A patent/CR20140179A/es unknown
- 2014-04-28 CU CUP2014000049A patent/CU20140049A7/es unknown
- 2014-05-01 IL IL232425A patent/IL232425A/en active IP Right Grant
- 2014-05-02 TN TNP2014000195A patent/TN2014000195A1/fr unknown
- 2014-05-06 PH PH12014501032A patent/PH12014501032A1/en unknown
- 2014-05-09 NI NI201400042A patent/NI201400042A/es unknown
- 2014-05-09 GT GT201400090A patent/GT201400090A/es unknown
- 2014-05-09 DO DO2014000098A patent/DOP2014000098A/es unknown
- 2014-05-09 CO CO14100184A patent/CO6960543A2/es unknown
- 2014-05-12 MA MA37018A patent/MA35638B1/fr unknown
- 2014-05-16 ZA ZA2014/03589A patent/ZA201403589B/en unknown
- 2014-06-09 US US14/299,497 patent/US9399626B2/en not_active Expired - Fee Related
- 2014-06-11 EC ECIEPI20144595A patent/ECSP14004595A/es unknown
- 2014-10-07 HK HK14109952.1A patent/HK1196603A1/zh not_active IP Right Cessation
-
2016
- 2016-06-24 US US15/191,943 patent/US9873673B2/en not_active Expired - Fee Related
- 2016-11-17 IL IL249039A patent/IL249039B/en active IP Right Grant
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU20140049A7 (es) | 2-tiopirimidinonas utiles como inhibidores de mieloperoxidasa | |
DOP2014000212A (es) | Compuestos inhibidores de beta-lactamasas | |
CR20160296A (es) | Benzamidas sustituidas y métodos para usarlas | |
ECSP13013074A (es) | Nuevos derivados de piridina | |
NI201200192A (es) | Derivados de imidazopiridina, su procedimiento de preparación y su aplicación en terapéutica. | |
CR20150078A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
CO6430459A2 (es) | Derivados de prolina como inhibidores de catepsina | |
CR20150250A (es) | Nuevos derivados de piridina | |
MA38050A1 (fr) | Inhibiteurs de gdf-8 | |
CR20140294A (es) | Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina | |
CL2011002433A1 (es) | Compuestos tetraciclicos, inhibidores de alk; composicion farmaceutica que comprende dichos compuestos, utiles en la profilaxis o el tratamiento de cancer, metastasis de cancer, depresion o un trastorno de la funcion cognitiva. | |
CR20140301A (es) | Derivados de betulina | |
GT201200230A (es) | Inhibidores del virus de la hepatitis c | |
CR20150447A (es) | Nuevos derivados de pirazol | |
UY33489A (es) | Derivados de indolizina, su procediemiento de preparacion y su aplicacion en terapeutica | |
CR20150204A (es) | Nuevos derivados de piridina | |
ECSP11011420A (es) | Procedimientos para mejorar la farmacocinética | |
GT201300085A (es) | Combinaciones que contienen n-(2-arilamino) arilsulfonamida sustituida | |
CU23854B1 (es) | Nuevos compuestos heterocíclicos nitrogenados y medicamento antibacteriano que los comprende | |
ES2572052T3 (es) | Amidas macrocíclicas como inhibidores de proteasas | |
CL2014001399A1 (es) | Compuestos de reversion anticoagulante; composicion farmaceutica y el uso de los mismos para revertir el efecto anticoagulante de un inhibidor de la coagulacion. | |
UY33305A (es) | Compuestos heterocíclicos inhibidores de DGAT1 | |
CO6700872A2 (es) | Derivados de 1,4-oxazepano | |
MX2018002479A (es) | Derivados antibacterianos pirrolidin-2-ona anulados. | |
CY1113983T1 (el) | Νεα μεθοδος συνθεσης της ιβαμπραδινης και των αλατων προσθηκης αυτης με ενα φαρμακευτικως αποδεκτο οξυ |